Due to his deep expertise in small molecule structural obviousness determinations, Bob has served as of counsel in US and foreign patent litigation matters including defense of patent rights covering the antipsychotic olanzapine and its use for the treatment of schizophrenia. He also served as a corporate representative to the Protect Trade Secrets Coalition that was instrumental in the 2016 passage of the Federal Defend Trade Secrets Act.
Bob has been actively involved with the Chemical Practice and Trade Secret Committees of the American Intellectual Property Law Association. He has taught collegiate classes in general and organic chemistry, and high school chemistry and physics. Bob also volunteers his time as pro bono counsel to nonprofit organizations and small businesses.
Prior to becoming an attorney, Bob had a successful career as a process chemist for Warner Lambert and a research chemist for Eli Lilly and Company. His research resulted in the grant of 20 patents encompassing novel molecules and synthetic processes.